Arrowhead REDEMPLO siRNA Drug Approved in Australia
Pasadena, USA | May 1, 2026 Arrowhead Pharmaceuticals has received approval from Australia’s Therapeutic Goods Administration (TGA) for REDEMPLO®...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
Pasadena, USA | May 1, 2026 Arrowhead Pharmaceuticals has received approval from Australia’s Therapeutic Goods Administration (TGA) for REDEMPLO®...
Pittsburgh, USA | May 1, 2026 Viatris has announced multiple clinical data presentations for its investigational low-dose estrogen combined...
